Gestational diabetes mellitus (GDM) is any degree of glucose intolerance with onset or first recognition during pregnancy.
Hyperglycemia in pregnancy may be suggested by the presence of glycosuria, a fetus that is large for date, or polyhydramnios.
Overt diabetes mellitus may be found in women presenting with risk factors for type 2 diabetes during the first prenatal visit (before 13 weeks of gestation).
Women with pre-eclampsia or gestational hypertension during their first pregnancy had an increased risk of developing chronic hypertension, type 2 diabetes (T2D), and hypercholesterolaemia than those who were normotensive during pregnancy, according to a study. The risk persisted for several decades later, signalling these hypertensive disorders of pregnancy (HDP) as red flags for cardiovascular (CV) health for life.
Elevated levels of the free thyroid hormone T3 (fT3) and a higher fT3/fT4 ratio in early pregnancy may point to a greater risk of developing gestational diabetes (GDM), according to a recent US-based study.
Women with gestational diabetes (GDM) or hypertensive disorders of pregnancy (HDP) were threefold more likely than those without these conditions to develop abnormal glucose metabolism or high blood pressure (BP), respectively after delivery, according to the GUSTO* study.
Women who breastfed their infants for a longer duration appeared to have a lower risk of diabetes compared with women who did not breastfeed, according to an observational study spanning three decades.
Adding continuous glucose monitoring (CGM) to conventional finger-prick test during pregnancy increases the time spent in the recommended glycaemic target range and improves neonatal health outcomes in patients with type 1 diabetes (T1D) compared with traditional test alone, according to the CONCEPTT* study presented at EASD 2017.
A healthy diet and regular exercise during pregnancy can limit gestational weight gain without adverse effects on offspring outcomes, along with reduced risks of caesarean section and gestational diabetes, according to a systematic review and meta-analysis by the i-WIP* Collaborative Group.
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.